System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Florent Peyraud is an expert in Oncology at Institut Bergonié (France). Florent Peyraud has authored 51 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 2 of them ongoing. SLR score: 303 (community average: 125). How the SLR is computed.

LeadR Profile

Florent Peyraud Institut Bergonié France
303 ScienceLeadR Reputation 303

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Hematology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2017 - 2026
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 51

Citations

Citations: 714 1st author: 13 Last author: 0 Unique author: 0

Main journals

Cancer Res 12
J Clin Oncol 7
Ann Oncol 6
Regular and Young Investigator Award Abstracts 6
Cancer Treat Rev 2

Best Journals

J Clin Oncol 7
Ann Oncol 6
Mol Cancer 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarker.
PMID 41699340 — neoplasms, biomarkers, sarcoma, clinical medicine		Clin Exp Med20260
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.
PMID 40579407 — cells, cold temperature, neoplasms, sarcoma, signal transduction, therapeutics, tissues, tumor microenvironment		Signal Transduct Target Ther Top journal20250
Immunosuppressive myeloid cells induce mesenchymal-like breast cancer stem cells by a mechanism involving membrane-bound TGF-β1.
OpenAlex W4408007263 — cells, microscopy, electron, scanning transmission, breast neoplasms, neoplasms, stem cells, myeloid cells, breast, membranes		bioRxiv (Cold Spring Harbor Laboratory)20250
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures.
PMID 39909044 — cells, neoplasms, carcinoma, non-small-cell lung, tertiary lymphoid structures, immunotherapy, fibroblasts		Cell Rep Med202524
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside.
PMID 39798544 — neoplasms, tertiary lymphoid structures, immunotherapy, immunity, therapeutics		Med20253

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 2
Phase 2 2
Phase 1 1
Phase 1/Phase 2 1
Phase 3 1

By status:

Recruiting 4
Active not recruiting 1
Completed 1
Terminated 1

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 3
multicentricup10 4

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Tumor Agnostic Precision Immuno Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
2023-507418-28-00 — neoplasms		Phase 2Active not recruiting2021
An Open Label Multicenter Multi Arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU 1805 in Adults with Advanced Solid Tumors
2022-502757-34-00 — safety, neoplasms, multiple chronic conditions, pharmacokinetics		Phase 1Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS